GB201519195D0 - CGRP Receptor Antagonists - Google Patents

CGRP Receptor Antagonists

Info

Publication number
GB201519195D0
GB201519195D0 GBGB1519195.0A GB201519195A GB201519195D0 GB 201519195 D0 GB201519195 D0 GB 201519195D0 GB 201519195 A GB201519195 A GB 201519195A GB 201519195 D0 GB201519195 D0 GB 201519195D0
Authority
GB
United Kingdom
Prior art keywords
receptor antagonists
cgrp receptor
cgrp
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1519195.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB1519195.0A priority Critical patent/GB201519195D0/en
Publication of GB201519195D0 publication Critical patent/GB201519195D0/en
Priority to AU2016344688A priority patent/AU2016344688A1/en
Priority to BR112018008419A priority patent/BR112018008419A2/pt
Priority to SG11201803380RA priority patent/SG11201803380RA/en
Priority to ARP160103295A priority patent/AR106488A1/es
Priority to PCT/IB2016/056518 priority patent/WO2017072722A1/en
Priority to EP16791444.9A priority patent/EP3368536B1/en
Priority to US15/336,880 priority patent/US9802935B2/en
Priority to JP2018541592A priority patent/JP6874013B2/ja
Priority to TW105135023A priority patent/TW201722952A/zh
Priority to CN201680063997.2A priority patent/CN108431005B/zh
Priority to CA3002623A priority patent/CA3002623A1/en
Priority to US15/708,424 priority patent/US10259812B2/en
Priority to IL258893A priority patent/IL258893A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1519195.0A 2015-10-30 2015-10-30 CGRP Receptor Antagonists Ceased GB201519195D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1519195.0A GB201519195D0 (en) 2015-10-30 2015-10-30 CGRP Receptor Antagonists
CA3002623A CA3002623A1 (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists
EP16791444.9A EP3368536B1 (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists
JP2018541592A JP6874013B2 (ja) 2015-10-30 2016-10-28 Ｃｇｒｐ受容体アンタゴニスト
SG11201803380RA SG11201803380RA (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists
ARP160103295A AR106488A1 (es) 2015-10-30 2016-10-28 Antagonistas de receptores de cgrp
PCT/IB2016/056518 WO2017072722A1 (en) 2015-10-30 2016-10-28 Cgrp receptor antagonists
AU2016344688A AU2016344688A1 (en) 2015-10-30 2016-10-28 CGRP receptor antagonists
US15/336,880 US9802935B2 (en) 2015-10-30 2016-10-28 CGRP receptor antagonists
BR112018008419A BR112018008419A2 (pt) 2015-10-30 2016-10-28 antagonistas do receptor cgrp
TW105135023A TW201722952A (zh) 2015-10-30 2016-10-28 Ｃｇｒｐ受體拮抗劑
CN201680063997.2A CN108431005B (zh) 2015-10-30 2016-10-28 Cgrp受体拮抗剂
US15/708,424 US10259812B2 (en) 2015-10-30 2017-09-19 CGRP receptor antagonists
IL258893A IL258893A (en) 2015-10-30 2018-04-24 Cgrp receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519195.0A GB201519195D0 (en) 2015-10-30 2015-10-30 CGRP Receptor Antagonists

Publications (1)

Publication Number Publication Date
GB201519195D0 true GB201519195D0 (en) 2015-12-16

Family

ID=55130447

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1519195.0A Ceased GB201519195D0 (en) 2015-10-30 2015-10-30 CGRP Receptor Antagonists

Country Status (13)

Country Link
US (2) US9802935B2 (https=)
EP (1) EP3368536B1 (https=)
JP (1) JP6874013B2 (https=)
CN (1) CN108431005B (https=)
AR (1) AR106488A1 (https=)
AU (1) AU2016344688A1 (https=)
BR (1) BR112018008419A2 (https=)
CA (1) CA3002623A1 (https=)
GB (1) GB201519195D0 (https=)
IL (1) IL258893A (https=)
SG (1) SG11201803380RA (https=)
TW (1) TW201722952A (https=)
WO (1) WO2017072722A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201908430D0 (en) 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
GB201908420D0 (en) 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
US20240327407A1 (en) * 2021-01-05 2024-10-03 Cadila Heal Thcare Limited Novel inhibitors of autotaxin
EP4516793A4 (en) * 2022-04-29 2025-08-27 Brise Pharmaceuticals Co Ltd PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, ITS PREPARATION PROCESS AND USE
WO2024046223A1 (zh) * 2022-08-30 2024-03-07 熙源安健医药（上海）有限公司 吲唑甲酰胺类衍生物及其制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
BRPI0311812B8 (pt) * 2002-06-05 2021-05-25 Bristol Myers Squibb Co antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
CA2519475A1 (en) * 2003-03-14 2004-09-30 Merck & Co., Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
CA2549330A1 (en) 2003-12-05 2005-07-21 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US20050233980A1 (en) 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2006006490A1 (ja) * 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
AU2005295855B2 (en) 2004-10-14 2011-08-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists
AU2005299852B2 (en) 2004-10-22 2011-08-04 Merck Sharp & Dohme Corp. CGRP receptor antagonists
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
PE20080370A1 (es) 2006-06-08 2008-06-13 Boehringer Ingelheim Int Derivados de quinazolinona como antagonistas de cgrp
CA2705405A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
TW201031665A (en) * 2009-02-04 2010-09-01 Gruenenthal Gmbh Substituted indole-compound
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8481546B2 (en) 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists

Also Published As

Publication number Publication date
CA3002623A1 (en) 2017-05-04
IL258893A (en) 2018-06-28
WO2017072722A1 (en) 2017-05-04
SG11201803380RA (en) 2018-05-30
US10259812B2 (en) 2019-04-16
US20180009808A1 (en) 2018-01-11
US9802935B2 (en) 2017-10-31
CN108431005A (zh) 2018-08-21
AU2016344688A1 (en) 2018-05-17
BR112018008419A2 (pt) 2018-11-06
US20170121331A1 (en) 2017-05-04
JP6874013B2 (ja) 2021-05-19
CN108431005B (zh) 2020-12-25
AR106488A1 (es) 2018-01-17
TW201722952A (zh) 2017-07-01
EP3368536B1 (en) 2019-03-06
EP3368536A1 (en) 2018-09-05
JP2018532789A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
IL258892B (en) Calcitonin gene-related peptide receptor antagonists
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
PL3515887T3 (pl) Antagoniści trpv4
IL258893A (en) Cgrp receptor antagonists
IL258737A (en) Antagonists ep4
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
ZA201800452B (en) Cgrp receptor antagonists
GB201702617D0 (en) Receptor
IL267686A (en) Integrin antagonists
IL244356B (en) Formulations for cgrp receptor antagonists
IL258894A (en) Cgrp receptor antagonists
GB201715008D0 (en) TRPV2 Antagonists
GB201702174D0 (en) Orexin receptor antagonists
EP3865472C0 (en) THROMBOXANE RECEPTOR ANTAGONISTS
IL252903A0 (en) cgrp antagonist peptides
GB201707499D0 (en) Orexin receptor antagonists
GB201507202D0 (en) Receptor tyosine kinase biomarkers
ZA201807767B (en) Angiotensin-1-receptor antagonists
PT3464324T (pt) Antagonistas de recetores da angiotensina-1
ZA201704249B (en) Cgrp antagonist peptides
GB201707504D0 (en) Orexin receptor antagonists
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
TH1601001484A (th) สูตรผสมสำหรับ cgrp รีเซปเตอร์แอนตะกอนิสต์

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)